Measles/Rubella

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

TakedaTOKYO, Japan

1 program

Freeze-dried live attenuated measles and rubella combined vaccineN/AVaccine2 trials

Active Trials

NCT02158364Completed3,331Est. Feb 2011

NCT02151773Completed3,493Est. Apr 2009

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

TakedaFreeze-dried live attenuated measles and rubella combined vaccine

Clinical Trials (2)

Total enrollment: 6,824 patients across 2 trials

NCT02158364 TakedaFreeze-dried live attenuated measles and rubella combined vaccine

Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination

Start: Mar 2007Est. completion: Feb 20113,331 patients

N/ACompleted

NCT02151773 TakedaFreeze-dried live attenuated measles and rubella combined vaccine

Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination

Start: Feb 2006Est. completion: Apr 20093,493 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.